Poor stem cell mobilisers -variation in response to G-CSF dose escalation
The juxtaposition of the papers on stem cell harvesting by Lie et al 1 and Clark and Brammer 2 highlight a problem of considerable significance in patients in whom stem cell transplantation offers the potential of salvage and/or cure. Between 13% 3 and 19% 1 of patients fail to mobilise sufficient stem cells for safe transplantation with conventional mobilisation techniques. In addition it is known that occasional normal PBSC donors fail to mobilise with conventional doses of G-CSF. As patients who may mobilise PBSC poorly are likely also to have poor quality marrow, alternative methods of obtaining adequate stem cell harvests are of considerable interest. The process of mobilisation is not yet well understood. It is possible that some patients who mobilise stem cells poorly will be adversely affected by even small amounts of prior chemotherapy.
The paper by Clark and Brammer 2 validates our previously described chemotherapy scoring system. 4 Unfortunately the prior chemotherapy status of the patients of Lie et al is not described. However, the data of Lie et al is interesting in that they suggest that there are at least two subgroups of patients who mobilise poorly -those who respond to additional G-CSF and those in whom an increment in G-CSF has no demonstrable impact.
Briefly, between March 1995 and February 1997 and after excluding patients with any form of leukaemia, repeat harvests and harvests from patients previously transplanted, we identified 14 patients (22%) who failed to mobilise adequate numbers of peripheral blood stem cells. Of these patients, nine had a second mobilisation procedure carried out using the same chemotherapy as for their first mobilisation (cyclophosphamide 1.5 g/m 2 i.v. on day 1) but with G-CSF dose-escalation to two vials daily. Their diagnosis, clinical details and previous chemotherapy score are shown in Table 1 . The outcome of the two aphereses in terms of total CD34-positive cells per kg is illustrated in Figure 1 for eight of these patients. Patient nine is not illustrated as his second apheresis was aborted after a poor yield on day 1. It can be seen that three patients mobilised significantly greater numbers of stem cells in response to the additional G-CSF. The remaining patients showed no difference. The variation in response did not appear to relate to age, previous chemotherapy score, diagnosis or clinical status.
Comparison of Figure 1 with Figure 2 of Lie et al 1 shows considerable similarity; in their group of 10 patients, seven patients had significant increases in stem cell mobilisation while three patients failed to show any increase whatsoever. These data appear to indicate that there may be subclasses of patients, ie those responding to G-CSF and those showing no incremental increase in stem cell mobilisation with increased G-CSF. In this latter group it is possible that the mobilisation seen is related solely to the chemotherapy used for mobilisation in conjunction with G-CSF rather than to the combined effect. Alternatively, it is also possible that the dose of 5 g/kg of G-CSF represents maximum stimulation for the G-CSF-sensitive cells whereas the patients with increased CD34-positive cell levels are capable of responding to higher doses of G-CSF With the advent of new cytokines with significant mobilisation ability 5 it will be important to evaluate these agents in conjunction with assessments of prior chemotherapy in order to identify optimal mobilisation techniques for the greatest number of patients possible.
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